The first patient to receive the novel cancer medicine AOH1996 from City of Hope is doing well in a Phase 1 clinical trial. The investigational pill has been effective in preclinical research treating various types of cancer cells. The treatment targets proliferating cell nuclear antigen (PCNA) and inhibits the growth and spread of cancer cells without harming healthy cells. The objective of the trial is to determine the maximum tolerated dose of AOH1996 and evaluate its preliminary efficacy. The medicine could potentially be used in combination with existing therapies to enhance cancer-killing effects and decrease side effects.

The post Molecule that Kills Most Solid Cancer Tumor Cells Leaving Others Unaffected Shows Promise After 20 Years’ Hard Work appeared first on Balanced News Summary.